SYH2095

SYH2095 is an orally bioavailable small molecule inhibitor of Ubiquitin-Specific Protease 1 (USP1), currently under development by CSPC Pharmaceutical Group (through its subsidiaries Hangzhou Yingchuang and CSPC Zhongqi) for the treatment of advanced malignant solid tumors. USP1 is a deubiquitinating enzyme that plays a critical role in the DNA damage response, specifically within the Fanconi anemia pathway and translesion synthesis, by deubiquitinating substrates such as FANCD2 and PCNA. By inhibiting USP1, SYH2095 prevents the deubiquitination of these key proteins, leading to the accumulation of ubiquitinated substrates, disruption of DNA repair mechanisms, and induction of synthetic lethality in cancer cells with homologous recombination deficiency (HRD), such as those harboring BRCA1/2 mutations. The drug is currently being evaluated in Phase I clinical trials in China to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors who have failed standard therapies.

Other names

SYH2095SYH-2095SYH 2095